How do medical device manufacturers achieve CE marking under the MDR without delays from the notified body?

CE marking under the Medical Device Regulation (EU) 2017/745 is not a step added at the end, but the visible consequence of a completed conformity assessment procedure. Sequence is what matters: first, classification under Annex VIII establishes the assessment route and thereby whether a notified body must be involved. Only after that is it worth building the technical documentation under Annex II and III, because its scope depends on the route. Within it, every General Safety and Performance Requirement from Annex I needs concrete evidence, and the clinical evaluation under Annex XIV is part of that. Anyone who checks the class too late, or requests notified body capacity only after writing the dossier, loses precisely this sequence as the bottleneck.

This is exactly where we come in: we confirm the class and the assessment route early, secure the QMS under ISO 13485:2016 in parallel as a prerequisite of the procedure, and build the technical documentation so that it passes the notified body review without rounds of additional requests. The declaration of conformity and affixing the CE marking then stand at the end of a straight path rather than at the beginning of a correction loop, and the post-market obligations take effect from day one after market entry.